Genetic and pharmacological interrogation of cancer vulnerability using a multiplexed cell line screening platform

The multiplexed cancer cell line screening platform PRISM demonstrated its utility in testing hundreds of cell lines in a single run, possessing the potential to speed up anti-cancer drug discovery, validation and optimization. Here we described the development and implementation of a next-generatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Yifeng, Ji, Xiaodong, Jang, In Sock, Surka, Christine, Hsu, Christy, Wang, Kai, Rolfe, Mark, Bence, Neil, Lu, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253734/
https://www.ncbi.nlm.nih.gov/pubmed/34215850
http://dx.doi.org/10.1038/s42003-021-02352-2
_version_ 1783717576871772160
author Xia, Yifeng
Ji, Xiaodong
Jang, In Sock
Surka, Christine
Hsu, Christy
Wang, Kai
Rolfe, Mark
Bence, Neil
Lu, Gang
author_facet Xia, Yifeng
Ji, Xiaodong
Jang, In Sock
Surka, Christine
Hsu, Christy
Wang, Kai
Rolfe, Mark
Bence, Neil
Lu, Gang
author_sort Xia, Yifeng
collection PubMed
description The multiplexed cancer cell line screening platform PRISM demonstrated its utility in testing hundreds of cell lines in a single run, possessing the potential to speed up anti-cancer drug discovery, validation and optimization. Here we described the development and implementation of a next-generation PRISM platform combining Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9-mediated gene editing, cell line DNA barcoding and next-generation sequencing to enable genetic and/or pharmacological assessment of target addiction in hundreds of cell lines simultaneously. Both compound and CRISPR-knockout PRISM screens well recapitulated the results from individual assays and showed high consistency with a public database.
format Online
Article
Text
id pubmed-8253734
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-82537342021-07-20 Genetic and pharmacological interrogation of cancer vulnerability using a multiplexed cell line screening platform Xia, Yifeng Ji, Xiaodong Jang, In Sock Surka, Christine Hsu, Christy Wang, Kai Rolfe, Mark Bence, Neil Lu, Gang Commun Biol Article The multiplexed cancer cell line screening platform PRISM demonstrated its utility in testing hundreds of cell lines in a single run, possessing the potential to speed up anti-cancer drug discovery, validation and optimization. Here we described the development and implementation of a next-generation PRISM platform combining Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9-mediated gene editing, cell line DNA barcoding and next-generation sequencing to enable genetic and/or pharmacological assessment of target addiction in hundreds of cell lines simultaneously. Both compound and CRISPR-knockout PRISM screens well recapitulated the results from individual assays and showed high consistency with a public database. Nature Publishing Group UK 2021-07-02 /pmc/articles/PMC8253734/ /pubmed/34215850 http://dx.doi.org/10.1038/s42003-021-02352-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Xia, Yifeng
Ji, Xiaodong
Jang, In Sock
Surka, Christine
Hsu, Christy
Wang, Kai
Rolfe, Mark
Bence, Neil
Lu, Gang
Genetic and pharmacological interrogation of cancer vulnerability using a multiplexed cell line screening platform
title Genetic and pharmacological interrogation of cancer vulnerability using a multiplexed cell line screening platform
title_full Genetic and pharmacological interrogation of cancer vulnerability using a multiplexed cell line screening platform
title_fullStr Genetic and pharmacological interrogation of cancer vulnerability using a multiplexed cell line screening platform
title_full_unstemmed Genetic and pharmacological interrogation of cancer vulnerability using a multiplexed cell line screening platform
title_short Genetic and pharmacological interrogation of cancer vulnerability using a multiplexed cell line screening platform
title_sort genetic and pharmacological interrogation of cancer vulnerability using a multiplexed cell line screening platform
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253734/
https://www.ncbi.nlm.nih.gov/pubmed/34215850
http://dx.doi.org/10.1038/s42003-021-02352-2
work_keys_str_mv AT xiayifeng geneticandpharmacologicalinterrogationofcancervulnerabilityusingamultiplexedcelllinescreeningplatform
AT jixiaodong geneticandpharmacologicalinterrogationofcancervulnerabilityusingamultiplexedcelllinescreeningplatform
AT janginsock geneticandpharmacologicalinterrogationofcancervulnerabilityusingamultiplexedcelllinescreeningplatform
AT surkachristine geneticandpharmacologicalinterrogationofcancervulnerabilityusingamultiplexedcelllinescreeningplatform
AT hsuchristy geneticandpharmacologicalinterrogationofcancervulnerabilityusingamultiplexedcelllinescreeningplatform
AT wangkai geneticandpharmacologicalinterrogationofcancervulnerabilityusingamultiplexedcelllinescreeningplatform
AT rolfemark geneticandpharmacologicalinterrogationofcancervulnerabilityusingamultiplexedcelllinescreeningplatform
AT benceneil geneticandpharmacologicalinterrogationofcancervulnerabilityusingamultiplexedcelllinescreeningplatform
AT lugang geneticandpharmacologicalinterrogationofcancervulnerabilityusingamultiplexedcelllinescreeningplatform

Ejemplares similares